Biberach

The biopharmaceutical production facility G104.

The Biberach site, in the very South of Germany, is home to the largest research and development center within Boehringer Ingelheim’s global network. At this site, all research and development steps for chemical active ingredients as well as for biopharmaceuticals are processed. On top of that, Biberach is also one of the largest sites in Europe for the production of biopharmaceutical active ingredients on the basis of cell cultures. More than 6,500 employees work on the company grounds, which encompass more than 642,000 square meters.

Purification of recombinant protein solution in downstream development.

In 1946, Boehringer Ingelheim founded the Dr. Karl Thomae GmbH in Biberach. After several decades of collaboration, the German pharmaceutical business, with its locations in Ingelheim and Biberach, was restructured under one country management in 1993. Following this organizational change, both sites have focused on their designated areas within the pharmaceutical value chain: While Biberach conducts research and development, Ingelheim is responsible for production. One exception is the biopharmaceutical production, which is also located in Biberach.

Laboratory employee using a microscope.

Throughout the years, this site has seen continuous investments. One of the largest investments ever made by Boehringer Ingelheim is currently being realized here: the Biologicals Development Center (BDC). This latest addition to the vast company grounds includes highly modern laboratories, technologies, a production facility, and smart working areas. Upon inauguration, more than 500 employees will advance the development of innovative biopharmaceutical active ingredients there.